news 
Catalio Capital Closes Over $400M Fund IV
Venture capital firm Catalio Capital Management has announced the successful closing of its more than $400 million Fund IV. This new fund will continue to support the company’s thesis of investing in healthcare and biotechnology companies.
Since its founding in 2020, Catalio has made over 100 investments, according to Pitchbook data. The firm’s latest effort, Fund IV, has already backed 16 companies, including diagnostics company PinkDX and drug discovery startup Superluminal Medicines.
Catalio Capital’s previous funds have demonstrated success, with Fund III closing at $381 million in 2020 and Fund II securing $100 million the year prior. The biotech market has experienced a downturn in recent years, with funding dropping significantly in 2023 to just $12 billion compared to its peak of $152.3 billion in 2022.
Despite these challenges, Catalio Capital remains committed to its investment thesis in healthcare and biotechnology. The company’s experience and track record have earned it a reputation as a trusted partner for entrepreneurs and innovators in the life sciences sector.
Catalio Capital is expected to continue making investments across various stages from seed to Series C and beyond.
Source: techcrunch.com
